Dr. Vlad C. Sandulache
Claim this profileBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Studies Squamous Cell Carcinoma
Studies Oral Cancers
3 reported clinical trials
9 drugs studied
Area of expertise
1Squamous Cell Carcinoma
p16 positive
p16 negative
Stage IV
2Oral Cancers
p16 positive
p16 negative
Stage IV
Affiliated Hospitals
Clinical Trials Vlad C. Sandulache is currently running
Navigation Intervention
for Head and Neck Cancers
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: * Does ENDURE improve initiation of timely PORT relative to treatment as usual? * Does ENDURE improve initiation of timely PORT in regards to racial disparities relative to treatment as usual? * What are the mechanisms through which ENDURE improves timeliness to treatment?
Recruiting1 award N/A7 criteria
High-Dose vs Low-Dose Cisplatin with Radiation
for Head and Neck Cancer
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Recruiting1 award Phase 2 & 335 criteria
More about Vlad C. Sandulache
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Vlad C. Sandulache has experience with
- ENDURE
- Computed Tomography (CT)
- Neck Dissection
- Planar Imaging
- Sentinel Lymph Node Biopsy
- Imaging Agent
Breakdown of trials Vlad C. Sandulache has run
Squamous Cell Carcinoma
Oral Cancers
Oropharyngeal Cancer
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vlad C. Sandulache specialize in?
Vlad C. Sandulache focuses on Squamous Cell Carcinoma and Oral Cancers. In particular, much of their work with Squamous Cell Carcinoma has involved p16 positive patients, or patients who are p16 negative.
Is Vlad C. Sandulache currently recruiting for clinical trials?
Yes, Vlad C. Sandulache is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Vlad C. Sandulache has studied deeply?
Yes, Vlad C. Sandulache has studied treatments such as ENDURE, Computed Tomography (CT), Neck Dissection.
What is the best way to schedule an appointment with Vlad C. Sandulache?
Apply for one of the trials that Vlad C. Sandulache is conducting.
What is the office address of Vlad C. Sandulache?
The office of Vlad C. Sandulache is located at: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.